CAP2 and cancer: CAP2 is overexpressed in different cancer and is an unfavorable biomarker for prognostic prediction for patients affected by breast cancer (Xu et al., 2016), epithelial ovarian cancer (Adachi et al., 2020), malignante melanoma (Masugi et al., 2015), gastric cancer (Li et al., 2020), and glioma (Saker et al., 2020).